Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial
Autore:
Groothius, JR;
Indirizzi:
Abbott Int, No Hemisphere Expanded Access Study Grp, Abbott Pk, IL USA Abbott Int Abbott Pk IL USA Expanded Access Study Grp, Abbott Pk, IL USA
Titolo Testata:
PEDIATRIC INFECTIOUS DISEASE JOURNAL
fascicolo: 6, volume: 20, anno: 2001,
pagine: 628 - 630
SICI:
0891-3668(200106)20:6<628:SATOPA>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
REHOSPITALIZATION; GESTATION; INFANTS;
Keywords:
respiratory syncytial virus; premature infants; monoclonal antibodies; bronchopulmonary dysplasia; chronic lung disease; respiratory disease; infectious disease;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
7
Recensione:
Indirizzi per estratti:
Indirizzo: Groothius, JR Care of Simpson SJ, Abbott Labs, Dept R4RE, Bldg AP34-3,200 Abbott Pk Rd, Abbott Pk, IL 60064 USA Care of Simpson SJ Bldg AP34-3,200 Abbott Pk Rd Abbott Pk IL USA 60064
Citazione:
J.R. Groothius, "Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial", PEDIAT INF, 20(6), 2001, pp. 628-630

Abstract

An Expanded Access Study was conducted to collect additional safety data on palivizumab. Pre-term infants with or without bronchopulmonary dysplasia received palivizumab every 30 days during the respiratory syncytial virus season. Adverse events were low (6.9%) in the 565 subjects. Serious adverse events included hospitalization and 1 case of respiratory syncytial virus bronchiolitis not requiring hospitalization. This study reaffirms the safetyand tolerability of palivizumab.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 02:24:10